Alphamab Oncology (9966.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 8.46B |
| Enterprise Value | 8.33B |
| P/E Ratio | -30.69 |
| PEG Ratio | 0.25 |
| Price/Sales Ratio | 9.94 |
| Price/Book Ratio | 3.05 |
| Enterprise/Revenue | 9.72 |
| Enterprise/EBITDA | -38.21 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | -0.34 |
| Operating Margin | -0.38 |
AD
Management Effectiveness
| Return On Assets | -0.08 |
| Return On Equity | -0.1 |
Income Statement
| Revenue | 551.58M |
| Revenue/Share | 0.53 |
| Gross Profit | 426.67M |
| EBITDA | -84.64M |
| Net Income | -110.99M |
| Diluted EPS | -0.12 |
Balance Sheet
| Total Cash | 1.43B |
| Total Cash/Share | 1.48 |
| Total Debt | 268.36M |
| Total Debt/Equity | 0.16 |
| Current Ratio | 4.02 |
| Book Value Per Share | 1.73 |
Price History
| 52-Week Change | -52.49 |
| 52-Week High | 13.1 |
| 52-Week Low | 6.2 |
| Moving Average 50 Days | 8.09 |
| Moving Average 200 Days | 8.57 |
Statistics
| Average Volume | 1.17M |
| Shares Outstanding | 968.51M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
